ロード中...
A comparative study of nivolumab and axitinib in terms of overall survival, treatment continuation, and cost for patients with metastatic renal cell carcinoma
Nivolumab and axitinib has recommended as a second-line treatment in patients with metastatic renal cell carcinoma (mRCC) after tyrosine kinase inhibitor treatment. In this study, overall survival (OS), treatment continuation, and the cost of nivolumab and axitinib-the second-line treatment agents f...
保存先:
| 出版年: | Mol Clin Oncol |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
D.A. Spandidos
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7016520/ https://ncbi.nlm.nih.gov/pubmed/32064108 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2020.1978 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|